Selected research
Industry Research
Biosuperior Industry Research Report 2026
Market perspective
The global Biosuperior market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Biosuperior is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Biosuperior is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Biosuperior is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Biosuperior include Teva, Sanofi, Novo Nordisk, Merck and Co., Eli Lily and Company, Biogen, SERVIER, Porton Biopharma and F.Hoffmann-La Roche AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Biosuperior market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosuperior Market by Company
Teva
Sanofi
Novo Nordisk
Merck and Co.
Eli Lily and Company
Biogen
SERVIER
Porton Biopharma
F.Hoffmann-La Roche AG
CSL Behring GmbH
Biosuperior Segment by Type
Insulin Biobetters
Monoclonal Antibodies Biobetters
Erythropoietin Biobetters
G-CSF Biobetters
Others
Biosuperior Segment by Application
Genetic Disease
Diabetes
Neurological Disorders
Cancer
Others
Biosuperior Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosuperior market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosuperior and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosuperior.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosuperior manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosuperior by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosuperior in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Insulin Biobetters
- Monoclonal Antibodies Biobetters
- Erythropoietin Biobetters
- G-CSF Biobetters
- Others
Applications
- Genetic Disease
- Diabetes
- Neurological Disorders
- Cancer
- Others
Companies covered
- Teva
- Sanofi
- Novo Nordisk
- Merck and Co.
- Eli Lily and Company
- Biogen
- SERVIER
- Porton Biopharma
- F.Hoffmann-La Roche AG
- CSL Behring GmbH
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosuperior Market Size (2021-2032)
- 2.2.2 Global Biosuperior Sales (2021-2032)
- 2.2.3 Global Biosuperior Market Average Price (2021-2032)
- 2.3 Biosuperior by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Insulin Biobetters
- 2.3.3 Monoclonal Antibodies Biobetters
- 2.3.4 Erythropoietin Biobetters
- 2.3.5 G-CSF Biobetters
- 2.3.6 Others
- 2.4 Biosuperior by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Genetic Disease
- 2.4.3 Diabetes
- 2.4.4 Neurological Disorders
- 2.4.5 Cancer
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosuperior Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biosuperior Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Biosuperior Revenue of Manufacturers (2021-2026)
- 3.4 Global Biosuperior Average Price by Manufacturers (2021-2026)
- 3.5 Global Biosuperior Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biosuperior, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosuperior, Product Type & Application
- 3.8 Global Manufacturers of Biosuperior, Established Date
- 3.9 Global Biosuperior Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Biosuperior Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sanofi
- 4.2.1 Sanofi Company Information
- 4.2.2 Sanofi Business Overview
- 4.2.3 Sanofi Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sanofi Biosuperior Product Portfolio
- 4.2.5 Sanofi Recent Developments
- 4.3 Novo Nordisk
- 4.3.1 Novo Nordisk Company Information
- 4.3.2 Novo Nordisk Business Overview
- 4.3.3 Novo Nordisk Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novo Nordisk Biosuperior Product Portfolio
- 4.3.5 Novo Nordisk Recent Developments
- 4.4 Merck and Co.
- 4.4.1 Merck and Co. Company Information
- 4.4.2 Merck and Co. Business Overview
- 4.4.3 Merck and Co. Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Merck and Co. Biosuperior Product Portfolio
- 4.4.5 Merck and Co. Recent Developments
- 4.5 Eli Lily and Company
- 4.5.1 Eli Lily and Company Company Information
- 4.5.2 Eli Lily and Company Business Overview
- 4.5.3 Eli Lily and Company Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Eli Lily and Company Biosuperior Product Portfolio
- 4.5.5 Eli Lily and Company Recent Developments
- 4.6 Biogen
- 4.6.1 Biogen Company Information
- 4.6.2 Biogen Business Overview
- 4.6.3 Biogen Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Biogen Biosuperior Product Portfolio
- 4.6.5 Biogen Recent Developments
- 4.7 SERVIER
- 4.7.1 SERVIER Company Information
- 4.7.2 SERVIER Business Overview
- 4.7.3 SERVIER Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 SERVIER Biosuperior Product Portfolio
- 4.7.5 SERVIER Recent Developments
- 4.8 Porton Biopharma
- 4.8.1 Porton Biopharma Company Information
- 4.8.2 Porton Biopharma Business Overview
- 4.8.3 Porton Biopharma Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Porton Biopharma Biosuperior Product Portfolio
- 4.8.5 Porton Biopharma Recent Developments
- 4.9 F.Hoffmann-La Roche AG
- 4.9.1 F.Hoffmann-La Roche AG Company Information
- 4.9.2 F.Hoffmann-La Roche AG Business Overview
- 4.9.3 F.Hoffmann-La Roche AG Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 F.Hoffmann-La Roche AG Biosuperior Product Portfolio
- 4.9.5 F.Hoffmann-La Roche AG Recent Developments
- 4.10 CSL Behring GmbH
- 4.10.1 CSL Behring GmbH Company Information
- 4.10.2 CSL Behring GmbH Business Overview
- 4.10.3 CSL Behring GmbH Biosuperior Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 CSL Behring GmbH Biosuperior Product Portfolio
- 4.10.5 CSL Behring GmbH Recent Developments
5 Global Biosuperior Market Scenario by Region
- 5.1 Global Biosuperior Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biosuperior Sales by Region: 2021-2032
- 5.2.1 Global Biosuperior Sales by Region: 2021-2026
- 5.2.2 Global Biosuperior Sales by Region: 2027-2032
- 5.3 Global Biosuperior Revenue by Region: 2021-2032
- 5.3.1 Global Biosuperior Revenue by Region: 2021-2026
- 5.3.2 Global Biosuperior Revenue by Region: 2027-2032
- 5.4 North America Biosuperior Market Facts & Figures by Country
- 5.4.1 North America Biosuperior Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biosuperior Sales by Country (2021-2032)
- 5.4.3 North America Biosuperior Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Biosuperior Market Facts & Figures by Country
- 5.5.1 Europe Biosuperior Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biosuperior Sales by Country (2021-2032)
- 5.5.3 Europe Biosuperior Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Biosuperior Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosuperior Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biosuperior Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biosuperior Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosuperior Market Facts & Figures by Country
- 5.7.1 South America Biosuperior Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biosuperior Sales by Country (2021-2032)
- 5.7.3 South America Biosuperior Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Biosuperior Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosuperior Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biosuperior Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biosuperior Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Biosuperior Sales by Type (2021-2032)
- 6.1.1 Global Biosuperior Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Biosuperior Sales Market Share by Type (2021-2032)
- 6.2 Global Biosuperior Revenue by Type (2021-2032)
- 6.2.1 Global Biosuperior Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biosuperior Revenue Market Share by Type (2021-2032)
- 6.3 Global Biosuperior Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biosuperior Sales by Application (2021-2032)
- 7.1.1 Global Biosuperior Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Biosuperior Sales Market Share by Application (2021-2032)
- 7.2 Global Biosuperior Revenue by Application (2021-2032)
- 7.2.1 Global Biosuperior Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biosuperior Revenue Market Share by Application (2021-2032)
- 7.3 Global Biosuperior Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosuperior Value Chain Analysis
- 8.1.1 Biosuperior Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosuperior Production Mode & Process
- 8.2 Biosuperior Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosuperior Distributors
- 8.2.3 Biosuperior Customers
9 Global Biosuperior Analyzing Market Dynamics
- 9.1 Biosuperior Industry Trends
- 9.2 Biosuperior Industry Drivers
- 9.3 Biosuperior Industry Opportunities and Challenges
- 9.4 Biosuperior Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst